Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.
Rabeprazole is a proton pump inhibitor (PPI) presenting a very advantageous pharmacodynamic and pharmacokinetic profile over older PPIs. In particular, this drug has a very fast onset of action, due to a short activation time and a very high pKa, and may therefore be defined as a 'second generation' PPI. The aim of this article is to provide an update on the pharmacology and clinical profile of rabeprazole and its use in acid-related disorders, with a particular focus on its role in gastroesophageal reflux disease; in the treatment and prevention of duodenal and gastric ulcers and Zollinger-Ellison syndrome; in the therapy of the extraesophageal manifestations of gastroesophageal reflux disease (in particular the respiratory and ear, nose and throat ones); and in the eradication of Helicobacter pylori.
Pallotta
Stefano
S
University of Milan, Via GB Grassi, 74, 20157 Milano, MI, Italy. stefanopallotta@interfree.it
Pace
Fabio
F
Marelli
Silvia
S
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001471:Barrett Esophagus / Q000188:drug therapy; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D054328:Proton Pump Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D064750:Rabeprazole; D013276:Stomach Ulcer / Q000188:drug therapy; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D064750:Rabeprazole